OraSure Technologies, Inc. (NASDAQ:OSUR) Stock Position Increased by Renaissance Technologies LLC

Renaissance Technologies LLC grew its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 20.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,288,443 shares of the medical instruments supplier’s stock after purchasing an additional 391,100 shares during the period. Renaissance Technologies LLC owned approximately 3.09% of OraSure Technologies worth $9,749,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of OraSure Technologies by 1.9% during the first quarter. Vanguard Group Inc. now owns 5,409,028 shares of the medical instruments supplier’s stock worth $33,266,000 after buying an additional 99,572 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of OraSure Technologies by 8.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,906,687 shares of the medical instruments supplier’s stock worth $32,035,000 after purchasing an additional 301,558 shares in the last quarter. Cannell Capital LLC grew its stake in shares of OraSure Technologies by 25.8% in the fourth quarter. Cannell Capital LLC now owns 3,549,050 shares of the medical instruments supplier’s stock worth $29,102,000 after purchasing an additional 728,459 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of OraSure Technologies by 38.1% during the second quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after purchasing an additional 605,324 shares during the period. Finally, American Century Companies Inc. raised its stake in shares of OraSure Technologies by 30.1% during the second quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock valued at $7,710,000 after purchasing an additional 418,603 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Price Performance

Shares of OSUR opened at $4.41 on Tuesday. The firm’s 50 day moving average is $4.33 and its 200-day moving average is $4.91. OraSure Technologies, Inc. has a 12-month low of $3.91 and a 12-month high of $8.45. The stock has a market capitalization of $326.16 million, a P/E ratio of 14.70 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter. The company had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $53.35 million. OraSure Technologies had a return on equity of 9.15% and a net margin of 9.88%. As a group, equities research analysts forecast that OraSure Technologies, Inc. will post -0.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on OSUR shares. StockNews.com lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, August 17th. Evercore ISI increased their price target on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, OraSure Technologies currently has a consensus rating of “Hold” and an average target price of $6.67.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.